Skip to main content

Scalp Psoriasis

Immunology
9
Pipeline Programs
5
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
4
1
Early DiscoveryClinical DevelopmentMarket

Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.

$15.0B marketMature↑ Growing30 products15 companies

Key Trends

  • JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
  • Multiple patent cliffs emerging 2026-2028, creating generic competition risk
  • Robust pipeline with 4,996 trials signals continued innovation and market expansion

Career Verdict

Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1MOUNJAROGrowing
$2.4B
#2SYMBICORTStable
$2.0B
AstraZeneca·LOE_APPROACHING
#3JAKAFIDeclining
$1.9B
Incyte·LOE_APPROACHING2.6yr
#4RESTASISStable
$1.5B
AbbVie·PEAK8.0yr
#5RINVOQGrowing
$976M
AbbVie·PEAK11.8yr

Drug Class Breakdown

Janus Kinase Inhibitors
$3.0B(20%)

dominant class with patent cliff risk

Corticosteroid Hormone Receptor Agonists
$2.8B(19%)

established, mature market segment

G-Protein-linked Receptor Interactions
$2.4B(16%)

driven by single blockbuster

Calcineurin Inhibitors
$1.6B(11%)

established immunosuppression class

Tumor Necrosis Factor Receptor Blocking Activity
$1.2B(8%)

legacy biologic class with competition

Career Outlook

Growing

Immunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.

Breaking In

Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.

For Experienced Professionals

Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.

In-Demand Skills

Medical Affairs and MSL expertise in immunosuppression and inflammatory diseasesJAK inhibitor mechanism expertise and competitive positioningClinical trial design and phase transition managementCommercial acumen for premium-priced biologics and small moleculesRegulatory strategy for label expansions and lifecycle management

Best For

Medical Science LiaisonBrand ManagerSenior Medical Affairs ManagerClinical Development ManagerCommercial Strategy Lead

Hiring Landscape

$212K-$387K

Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.

340
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

45Growing
31Growing
29Stable

By Department

Medical Affairs(32%)
$257K
Commercial(24%)
$270K
Research & Development(9%)
$387K
Clinical Operations(4%)
$345K
Manufacturing(2%)
$212K

Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Galderma
GaldermaTX - Dallas
3 programs
2
1
clobetasol propionate spray 0.05%Phase 41 trial
C. propionate - Corticosteroid 1Phase 31 trial
Clobex® ShampooPhase 31 trial
Active Trials
NCT00438399Completed219Est. Feb 2008
NCT00400725Completed288Est. Aug 2007
NCT00881868Completed81Est. Dec 2009
Leo Pharma
Leo PharmaDenmark - Ballerup
4 programs
2
1
Xamiol® gelPhase 31 trial
LEO 80185Phase 21 trial
LEO 80185Phase 21 trial
Xamiol® GelN/A1 trial
Active Trials
NCT01052467Completed724Est. May 2010
NCT01083758Completed31Est. Oct 2012
NCT01120223Completed78Est. Oct 2012
+1 more trials
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
Roflumilast Foam 0.3%Phase 31 trial
Active Trials
NCT05028582Completed432Est. Jun 2022
Eppendorf
EppendorfGermany - Hamburg
1 program
1
DimethiconePhase 21 trial
Active Trials
NCT01914627Completed90Est. Jan 2014
Tolmar
TolmarCO - Fort Collins
1 program
1
Calcipotriene and betamethasone suspensionPhase 11 trial
Active Trials
NCT03122353Completed699Est. Nov 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Galdermaclobetasol propionate spray 0.05%
BioTherapeutics IncRoflumilast Foam 0.3%
Leo PharmaXamiol® gel
GaldermaC. propionate - Corticosteroid 1
GaldermaClobex® Shampoo
EppendorfDimethicone
Leo PharmaLEO 80185
Leo PharmaLEO 80185
TolmarCalcipotriene and betamethasone suspension
Leo PharmaXamiol® Gel

Clinical Trials (10)

Total enrollment: 2,886 patients across 10 trials

NCT00881868Galdermaclobetasol propionate spray 0.05%

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

Start: Apr 2009Est. completion: Dec 200981 patients
Phase 4Completed
NCT05028582BioTherapeutics IncRoflumilast Foam 0.3%

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Start: Aug 2021Est. completion: Jun 2022432 patients
Phase 3Completed

Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis

Start: Sep 2010Est. completion: Mar 2011244 patients
Phase 3Completed
NCT00438399GaldermaC. propionate - Corticosteroid 1

Subject Preference for Scalp Psoriasis Treatment

Start: Feb 2007Est. completion: Feb 2008219 patients
Phase 3Completed
NCT00400725GaldermaClobex® Shampoo

Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis

Start: Sep 2006Est. completion: Aug 2007288 patients
Phase 3Completed

Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis

Start: Aug 2013Est. completion: Jan 201490 patients
Phase 2Completed

Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Start: May 2010Est. completion: Oct 201278 patients
Phase 2Completed

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Start: Apr 2010Est. completion: Oct 201231 patients
Phase 2Completed
NCT03122353TolmarCalcipotriene and betamethasone suspension

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

Start: Apr 2017Est. completion: Nov 2017699 patients
Phase 1Completed

Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Start: Jan 2010Est. completion: May 2010724 patients
N/ACompleted

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.